Allspring Global Investments
BCRX icon

Allspring Global Investments’s BioCryst Pharmaceuticals BCRX Stock Holding History

Allspring Global Investments’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,574
Closed -$79.3K – 1636
2025
Q1 		$79.3K Buy
+10,574
New +$85.3K ﹤0.01% 1699
2024
Q4 		– Sell
-101
Closed -$767 – 1823
2024
Q3 		$767 Buy
+101
New +$768 ﹤0.01% 2352
2023
Q4 		– Sell
-2,478
Closed -$17.5K – 2267
2023
Q3 		$17.5K Buy
2,478
+896
+57% +$6.44K ﹤0.01% 2533
2023
Q2 		$11.1K Sell
1,582
-3,689
-70% -$29.6K ﹤0.01% 2527
2023
Q1 		$44K Sell
5,271
-6,298
-54% -$60.6K ﹤0.01% 2324
2022
Q4 		$133K Sell
11,569
-253
-2% -$3.15K ﹤0.01% 1963
2022
Q3 		$148K Hold
11,822
– – ﹤0.01% 1916
2022
Q2 		$125K Sell
11,822
-118,438
-91% -$1.22M ﹤0.01% 1979
2022
Q1 		$2.12M Sell
130,260
-22,983
-15% -$369K ﹤0.01% 1473
2021
Q4 		$2.12M Buy
+153,243
New +$2.03M ﹤0.01% 1508

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Allspring Global Investments's BCRX Position: Q2 2025 in Review

Allspring Global Investments sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2025, closing a stake of 10,574 shares — an estimated $79.3K sold.

Allspring Global Investments first reported a position in BCRX in Q4 2021 and held it in 10 quarters. The position peaked at $2.12M in Q4 2021. 294 funds tracked by Wall St. Rank hold BCRX as of Q2 2025.

  • Allspring Global Investments reported no remaining BioCryst Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Allspring Global Investments sold 10,574 BioCryst Pharmaceuticals shares in Q2 2025, an estimated $79.3K.
  • Allspring Global Investments first reported a position in BioCryst Pharmaceuticals in Q4 2021 and held it in 10 quarters.
  • Allspring Global Investments's BioCryst Pharmaceuticals position peaked at $2.12M in Q4 2021.
  • 294 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2025.

Based on Allspring Global Investments's 13F filing for Q2 2025, filed 25 Jul 2025.